Heck Capital Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Heck Capital Advisors, LLC
- $1.47 Trillion
- Q4 2024
A detailed history of Heck Capital Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Heck Capital Advisors, LLC holds 605 shares of HALO stock, worth $33,656. This represents 0.0% of its overall portfolio holdings.
Number of Shares
605Holding current value
$33,656% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
538Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$980 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$717 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$369 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$226 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$190 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...